Article Details
Retrieved on: 2025-04-09 14:52:55
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses impending tariffs by Donald Trump on the pharmaceutical industry, affecting biopharma firms' operations, possibly increasing costs without ensuring domestic production benefits, and causing market uncertainty. Arthur Wong highlights manufacturing challenges amid these policy shifts. The concept, biopharma, and the tags emphasize impacts on pharma policies, infrastructure, and international dynamics involving India, China, and companies like WuXi Biologics.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here